Helix Acquisition Corp. II Completes Merger with BridgeBio

Helix Acquisition Corp. II Class A ( (HLXB) ) has shared an announcement.

On August 11, 2025, Helix Acquisition Corp. II completed a business combination with BridgeBio Oncology Therapeutics, Inc., resulting in Helix ceasing to be a shell company. This merger led to the newly formed PubCo’s common stock being listed on Nasdaq under the symbol ‘BBOT’. The merger also included amendments to the company’s charter and bylaws, which were approved by shareholders. The transition marks a significant step in the company’s growth, providing it with a platform for further development and expansion in the oncology therapeutics sector.

More about Helix Acquisition Corp. II Class A

Average Trading Volume: 82,716

Technical Sentiment Signal: Strong Sell

For an in-depth examination of HLXB stock, go to TipRanks’ Overview page.